Michael,
Have you ever given the hairy eyeball to QLT PhotoTherapeutics Inc (QLTI)? They make the drug, Visudyne, that is used in PhotoDynamic Treatment (PDT). In particular, its use in treating the wet form of macular generation is awaiting FDA approval. The wet form of macular generation affects half a million older people per year, causes almost total loss of central vision, and there is currently no treatment available for most of the cases.
Here is the conference call from last November. Of particular note is the fact that Medicare has indicated (prior to FDA approval!) that they would pay for the treatment.
Message 12049009
Since then, QLTI has gone up with the biotechs, then suffered somewhat when the FDA gave it only an "approvable" letter by the February deadline instead of full approval. It just means, as far as I can see, that they ran out of time to finish their review.
When Photodynamic Treatment for macular generation is approved, there is going to be a stampede. Hundreds of thousands of people (my father among them) are going blind inch by inch with no available treatment.
I'd love to see your opinion on this one.
BTW, thanks for VASO! I hope QLTI can pay back the tip. |
